MAC预处理自体骨髓移植治疗急性白血病  

Melphalan,Ara-C and cyclophosphamide following autologous bone marrow transplantation for acute leukemia

作　　者：宋永平[1] 魏旭东[1] 邹典斌[1] 刘长风[1] 王桂菊[1] 孙慧[1] 王桂叶[1] 白任奎[1] 万鼎铭[1] 胡大平[1] 吕先萍[1] 赵志平[1] 

机构地区：[1]河南医科大学第一附属医院

出　　处：《中华血液学杂志》1996年第10期513-515,共3页Chinese Journal of Hematology

基　　金：河南省卫生厅青年科学研究基金

摘　　要：为评价ＭＡＣ（马法兰、阿糖胞苷和环磷酰胺）预处理方案，应用该方案为１７例急性白血病患者进行了自体骨髓移植。结果：该方案具有清除骨髓白血病细胞的作用，移植后全部患者造血功能获得重建，无一例移植相关死亡。中位随访１８个月，５年无病生存率为５０．５％，其中急性髓系白血病（ＡＭＬ）为６１．２％。结果表明：ＭＡＣ预处理方案对ＡＭＬ有良好疗效，且髓外毒副作用较轻，值得进一步试用。To evaluate the effect of MAC(Melphalan,Ara-C and Cyclophosphamide)conditioning regimen,17 patients with acute leukemia were treated with autologous bone marrow transplantation(ABMT)following MAC conditioning.The results showed that MAC had ablative effect on bone marrow and the hematopoiesis was completely reconstituted in all patients.No patients died of complications associated with transplantation.The disease-free-survival(DFS)at 5 years post-ABMT were 50.5%for all patients and 61.2% for acute myeloid leukemia(AML)at a median follow-up of 18 months.It is suggested that MAC protocol might be a safe,effective and economic conditioning regimen for ABMT in AML.

关 键 词：急性 白血病 预处理方案 骨髓移植 自体移植 

分 类 号：R733.710.5[医药卫生—肿瘤]